3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure
Clinical Trial | By MJ Mack , J Lindenfeld, and for the COAPT Investigators et al.
BACKGROUND - In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) resulted in fewer heart failure hospitalizations (HFHs) and lower mortality at 24 months in patients with heart failure (HF) with mitral regurgitation (MR) secondary to left ventricular dysfunction compared w...
Original Research | By H Ota, H Omori, M Kawasaki et al.
AIMS - This study aimed to determine the effects of a proprotein convertase subtilisin-kexin type 9 inhibitor (PCSK9i) on coronary plaque volume and lipid components in patients with a history of coronary artery disease (CAD). METHODS AND RESULTS - This prospective, open-label, single-centre study analysed non-culprit coronary segments using near-infrared spectroscopy-intravascular ultr...
Original Research | By C Genz, RC Braun-Dullaeus.
BACKGROUND - Approximately 18% of patients with atrial fibrillation undergo a percutaneous coronary intervention (PCI) to treat coronary heart disease. Pharmacological anticoagulation in patients with atrial fibrillation and PCI involves a trade-off of potential ischemic and hemorrhagic complications. METHODS - This review is based on pertinent publications that were retrieved by a selective li...
Clinical Trial | By Elvin Kedhi 1 , Monica Verdoia,Giuseppe De Luca
BACKGROUND AND AIMS - The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patie...
Clinical Trial | By AJ Kirtane, R Stoler, R Feldman et al.
BACKGROUND - Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is associated with increased bleeding, despite a reduced incidence of ischemic events. The SYNERGY everolimus-eluting stent is a thin-strut platinum-chromium stent that elutes everolimus from a thin abluminal layer of bioabsorbable polymer. These design elements may facilitate rapid endothelialization and enable shorter-duration DAPT...
Original Research | By RJ Woolley, D Ceelen, W Ouwerkerk et al.
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk
Clinical Trial | By MB Leon , MJ Mack, and the PARTNER 3 Investigators.
BACKGROUND - In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year. OBJECTIVES ...
Clinical Trial | By SJ. Baron, EA Magnuson, the PARTNER 3 Investigators et al.
Clinical Trial | By TM Nazif, J Moses, REFLECT II Trial Investigators et al.
OBJECTIVES - The REFLECT II (Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Implantation) trial was designed to investigate the safety and efficacy of the TriGUARD 3 (TG3) cerebral embolic protection in patients undergoing transcatheter aortic valve replacement. BACKGROUND - Cerebral embolization occurs frequently following transcatheter ...